Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 94

Sort by

Sort Order Select

Journal Articles

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Blood (2025) 146 (Supplement 1): 930.

https://doi.org/10.1182/blood-2025-930

Published: 2025

Journal Articles

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Blood (2025) 146 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2025-4066

Published: 2025

Journal Articles

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Blood (2025) 146 (Supplement 1): 2214.

https://doi.org/10.1182/blood-2025-2214

Published: 2025

Journal Articles

Discovery of first-in-class calr-targeted precision ADCs delivering a CDK9degrader payload for the treatment of calr-mutated MPNs

Norman Fultang, Ashley Schwab, Sharayu Chandratre, Jake Karwoski, Grace Davis, Ian Johnson, Neha Bhagwat, Yue Zou, Arpita Mondal, Max Foroutan, Ryan Holmes, Chun Chen, Corey Basch, Andrew Buesking, Sang Hyun Lee, Diane Heiser, Andrew Combs, Peggy Scherle

Blood (2025) 146 (Supplement 1): 72.

https://doi.org/10.1182/blood-2025-72

Published: 2025

Journal Articles

Real-world cardiovascular risk of ponatinib in chronic Phase CML: Insights from a nationwide Korean claims-based cohort study

Jeong-Ok Lee, Ju-Hyun Lee, Eun-Jeong Jeong, Sang-A Kim, Ji Yun Lee, Soo-Mee Bang

Blood (2025) 146 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2025-1996

Published: 2025

Journal Articles

NB02 (Poseltinib) combined rituximab and lenalidomide in R/ R PCNSL (POTENTIAL-P): Initial results of safety lead-in cohort.

Deok-Hwan Yang, Sung Yong Oh, Youngwoo Jeon, Ga-Young Song, Seokjin Kim, Sang Eun Yoon, Tong-Yoon Kim, Ji Hyun Lee, Hye Ryeon Kim, Youngil Koh, Han Song, Myungsea Lee, Won Seog Kim

Blood (2025) 146 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2025-5463

Published: 2025

Journal Articles

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Blood (2025) 146 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2025-3646

Published: 2025

Journal Articles

Real-world insights into ATRA-based maintenance therapy and prognostic markers of relapse in acute promyelocytic leukemia

Kunye Kwak, Changgon Kim, Yoon Seok Choi, Ka-Won Kang, Byung Soo Kim, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Chul Won Choi, Byung-Hyun Lee, Se Ryeon Lee, Hwa Jung Sung, Mihee Kim, Seo-Yeon Ahn, Chang-Hoon Lee, Ho-Young Yhim, Jae-Sook Ahn, Yong Park

Blood (2025) 146 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2025-1609

Published: 2025

Journal Articles

Comprehensive analysis of long-term outcomes in adult patients with acute lymphoblastic leukemia who received allogeneic stem cell transplantation: Real-world data of the Korean society of blood and marrow transplantation registry

Dong Won Baek, Je-Hwan Lee, Joon Seong Park, Deok-Hwan Yang, Ji Hyun Lee, Yeung-Chul Mun, Ho Sup Lee, Ka-Won Kang, Seong Kyu Park, Chul Jung, Soo-Mee Bang, Joon Ho Moon

Blood (2025) 146 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2025-4286

Published: 2025

Journal Articles

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

Blood (2025) 146 (2): 155–166.

https://doi.org/10.1182/blood.2024027109

Published: 2025

Includes: Supplemental data

Journal Articles

Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Seok Jin Kim, SangEun Yoon, Ji Hyun Lee, Jeong-Ok Lee, Seong Hyun Jeong, Sung-Nam Lim, Ho-Jin Shin, Duck Hwan Yang, Won Seog Kim

Blood (2024) 144 (Supplement 1): 1683.

https://doi.org/10.1182/blood-2024-205026

Published: 2024

Journal Articles

Prognostic Impact of PTPN11 mutations in Acute Myeloid Leukemia

Thuy Ho, Luke Kicklighter, George Avetian, Graeme F Murray, Ian M. Bouligny, Hyun Lee, Natasha Dziarnowski, Keri Maher

Blood (2024) 144 (Supplement 1): 6120.

https://doi.org/10.1182/blood-2024-211478

Published: 2024

Journal Articles

Real-World Efficacy and Safety of Teclistamab for Patients with Released or Refractory Multiple Myeloma: Korean, Nationwide, Retrospective Analysis of an Named Patient Program

Jun Ho Yi, Jae Hoon Lee, Sung-Hoon Jung, Ji Hyun Lee, Ji Yun Lee, Kihyun Kim, Sung-Soo Park, Chang-Ki Min, Yoon Seok Choi, Min Kyoung Kim, Ho-Young Yhim, Dok Hyun Yoon

Blood (2024) 144 (Supplement 1): 7033.

https://doi.org/10.1182/blood-2024-207611

Published: 2024

Journal Articles

Dual-Center Experience of Using Etoposide for Secondary Hemophagocytic Lymphohistiocytosis from Infectious Etiologies

Hyun Lee, Andrea Lo, Shejal B. Patel

Blood (2024) 144 (Supplement 1): 5383.

https://doi.org/10.1182/blood-2024-210790

Published: 2024

Journal Articles

Leveraging Generative Artificial Intelligence in Diagnosis of Thrombotic Microangiopathies: Focus on Thrombotic Thrombocytopenic Purpura

Eunhee Choi, Jung-Hyun Lee, Robert McDougal, William W Lytton

Blood (2024) 144 (Supplement 1): 2616.

https://doi.org/10.1182/blood-2024-194769

Published: 2024

Journal Articles

Tumor-Primed CD3 + CD56 + natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma

Ji Hyun Lee, Seok-Ho Kim, Junsang Doh, Duck Cho, Jeong-a Kim, Sung Yong Oh, Sung-Hyun Kim, Juheon Lee

Blood (2024) 144 (Supplement 1): 2057.

https://doi.org/10.1182/blood-2024-200559

Published: 2024

Journal Articles

Shifting Treatment Paradigms and Clinical Outcomes in TP53 Mutated Acute Myeloid Leukemia

Hyun Lee, Luke Kicklighter, Thuy Ho, George Avetian, Graeme F Murray, Natasha Dziarnowski, Ian M. Bouligny, Keri Maher

Blood (2024) 144 (Supplement 1): 7909.

https://doi.org/10.1182/blood-2024-206123

Published: 2024

Journal Articles

Comparison of Cytoreductive Therapies for Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: A Perspective on the Updated American Society for Apheresis Guidelines

George Avetian, Thuy Ho, Ian M. Bouligny, Hyun Lee, Keri Maher

Blood (2024) 144 (Supplement 1): 7637.

https://doi.org/10.1182/blood-2024-206090

Published: 2024

Journal Articles

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Blood (2024) 144 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2024-205164

Published: 2024

Journal Articles

Retrospective Analysis of Treatment Outcome Differences with and without Autologous Stem Cell Transplantation in Patients with Dialysis-Dependent Multiple Myeloma (DDMM): KMM2304 Study

Myung-Won Lee, Sung-Hoon Jung, Chang-Ki Min, Kihyun Kim, Ho-Young Yhim, Dok Hyun Yoon, Sang Min Lee, Ho-Jin Shin, Jae-Cheol Jo, Jongheon Jung, Yundeok Kim, Jae Hoon Lee, Ji Hyun Lee, Sung-Hyun Kim

Blood (2024) 144 (Supplement 1): 7074.

https://doi.org/10.1182/blood-2024-210665

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Discovery of first-in-class calr-targeted precision ADCs delivering a CDK9degrader payload for the treatment of calr-mutated MPNs

Real-world cardiovascular risk of ponatinib in chronic Phase CML: Insights from a nationwide Korean claims-based cohort study

NB02 (Poseltinib) combined rituximab and lenalidomide in R/ R PCNSL (POTENTIAL-P): Initial results of safety lead-in cohort.

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Real-world insights into ATRA-based maintenance therapy and prognostic markers of relapse in acute promyelocytic leukemia

Comprehensive analysis of long-term outcomes in adult patients with acute lymphoblastic leukemia who received allogeneic stem cell transplantation: Real-world data of the Korean society of blood and marrow transplantation registry

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Prognostic Impact of PTPN11 mutations in Acute Myeloid Leukemia

Real-World Efficacy and Safety of Teclistamab for Patients with Released or Refractory Multiple Myeloma: Korean, Nationwide, Retrospective Analysis of an Named Patient Program

Dual-Center Experience of Using Etoposide for Secondary Hemophagocytic Lymphohistiocytosis from Infectious Etiologies

Leveraging Generative Artificial Intelligence in Diagnosis of Thrombotic Microangiopathies: Focus on Thrombotic Thrombocytopenic Purpura

Tumor-Primed CD3 + CD56 + natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma

Shifting Treatment Paradigms and Clinical Outcomes in TP53 Mutated Acute Myeloid Leukemia

Comparison of Cytoreductive Therapies for Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: A Perspective on the Updated American Society for Apheresis Guidelines

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Retrospective Analysis of Treatment Outcome Differences with and without Autologous Stem Cell Transplantation in Patients with Dialysis-Dependent Multiple Myeloma (DDMM): KMM2304 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only